Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2017/0136030 TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY
Compounds are disclosed that inhibit the methylerythritol cytidyltransferase (IspD) enzyme in the non-mevalonate pathway (MEP pathway), which is present in...
2017/0136029 DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a ...
2017/0136028 COMPOSITION AND METHOD FOR COMPOUNDED THERAPY
A method of compounding a transdermal cream may include grinding one or more tablets of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and one or more nerve...
2017/0136027 Aprepitant Injectable Formulations
An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent...
2017/0136026 COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates,...
2017/0136025 PHARMACEUTICAL PREPARATION CONTAINING ENTECAVIR AS ACTIVE INGREDIENT, AND PREPARATION METHOD THEREFOR
The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance...
2017/0136024 INHIBITORS OF E1 ACTIVATING ENZYMES
This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the...
2017/0136023 QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as...
2017/0136022 SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR
A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-.alpha.]pyridin-7-yloxy)-3-methylphenyl)-N6-(4- ,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and...
2017/0136021 METHODS AND COMPOSITIONS FOR TREATING ENVELOPED VIRUSES
Described are compositions and methods for treating an enveloped virus in a patient in need thereof. Exemplary enveloped viruses are those in the family...
2017/0136020 COMPOSITIONS COMPRISING DASATINIB FOR TREATING COMPLEX REGIONAL PAIN SYNDROME
Oral dosage forms of osteoclast inhibitors, including some Bruton's tyrosine kinase (BTK) inhibitors, such as dasatinib can be used to treat or alleviate pain...
2017/0136019 sGC STIMULATORS
Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds...
2017/0136018 Methods for Treating MS Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).
2017/0136017 LIVER X RECEPTOR MODULATORS
Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions...
2017/0136016 METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION
A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a...
2017/0136015 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS
Pharmaceutical compositions for topical administration for the treatment of psoriasis are described, containing as active ingredient therapeutically effective...
2017/0136014 Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor
Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K)...
2017/0136013 Method of Treating Hand-Foot Syndrome and Symptoms Associated Therewith
A method of treating hand-foot syndrome (palmar-plantar erythrodysesthesia) and symptoms associated therewith in a patient undergoing or scheduled to undergo...
2017/0136012 TREATMENT AND PROGNOSTIC MONITORING OF NON-CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers,...
2017/0136011 TREATMENT AND PROGNOSTIC MONITORING OF CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers,...
2017/0136010 ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING...
[Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that...
2017/0136009 DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: ##STR00001## It further discloses a...
2017/0136008 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER
A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an...
2017/0136007 NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
Disclosed are novel piperazine derivatives that act as agonists of the a7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating...
2017/0136006 METHODS OF MANUFACTURING ORAL DOSAGE FORMS
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a...
2017/0136005 METHODS OF TREATING OPIATE DEPENDENCY AND PREVENTING NON-ORAL OPIATE ABUSE AMONG OPIATE ADDICTS
The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on...
2017/0136004 Opioid Agonist Antagonist Combinations
The invention relates a composition comprising an opioid agonist and Compound-1: ##STR00001##
2017/0136003 TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an...
2017/0136002 Composition Containing Apomorphine And A Divalent Metal Cation
A composition containing apomorphine and a divalent metal cation, such as, for example, Zn.sup.2+, Ca.sup.2+, or Mg.sup.2+, is disclosed. The composition...
2017/0136001 METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS
The invention includes methods, compositions, and kits useful for treating a viral infection by administering ...
2017/0136000 METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS
The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering ...
2017/0135999 CONTROLLED RELEASE FORMULATIONS HAVING RAPID ONSET AND RAPID DECLINE OF EFFECTIVE PLASMA DRUG CONCENTRATIONS
The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of...
2017/0135998 Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy
Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be...
2017/0135997 TREATMENT OF FAMILIAL EXUDATIVE VITREORETINOPATHY THROUGH S1PR2 INHIBITION
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the...
2017/0135996 PHARMACEUTICAL DEPOT FOR N-{5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL)-3-FLUORO-4-(PYRIDIN-2-Y- ...
A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-y- lmethoxy)benzamide, or a...
2017/0135995 PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOF
The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in...
2017/0135994 NAMPT INHIBITORS
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is...
2017/0135993 PHARMACEUTICAL COMPOSITION CONTAINING FK506 DERIVATIVE FOR TREATING FUNGAL INFECTION CAUSED BY GENUS...
The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or...
2017/0135992 CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY
The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use...
2017/0135991 NANOPARTICULATE FORMULATION COMPRISING A mPGES-1 INHIBITOR
The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 ("mPGES-1") inhibitor. Particularly, the...
2017/0135990 PHARMACEUTICAL COMPOSITIONS COMPRISING A 5,5-FUSED HETEROARYLENE FLAVIVIRIDAE INHIBITOR AND THEIR USE FOR...
Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also...
2017/0135989 ALLISARTAN ISOPROXIL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION
The present invention provides an allisartan isoproxil solid dispersion with high drug loading and stability. On that basis, it also provides an allisartan...
2017/0135988 SYSTEM AND METHOD FOR PREVENTING ALOPECIA
Traction alopecia and other disorders related to mechanical pulling on hair are treated or prevented by administering a topical composition comprising an...
2017/0135987 THIOUREYLENE LIQUID COMPOSITIONS
The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The...
2017/0135986 STABILIZED MULTI-FUNCTIONAL ANTIOXIDANT COMPOUNDS AND METHODS OF USE
Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated...
2017/0135985 THERAPEUTIC/ PREVENTIVE AGENT CONTAINING COUMARIN DERIVATIVE AS ACTIVE INGREDIENT
A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed....
2017/0135984 INTRANASAL AND TRANSDERMAL ADMINISTRATION OF KAPPA-OPIOID-RECEPTOR AGONISTS: SALVINORIN A FOR THE TREATMENT OF...
Methods of treating neuropsychiatric disorders including affective disorders and addiction involve intranasal or transdermal administration of a substantially...
2017/0135983 COMPOSITION FOR REGULATING BLOOD SUGAR
The present invention provides a composition for regulating blood sugar. The composition comprises at least one yellow pigment extracted from a red mold...
2017/0135982 Hydroxyflavanones as Appetite Stimulants
The invention relates to compounds of formula (I) or the salts thereof, said compounds of formula (I) being selected from among the group consisting of...
2017/0135981 Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.